Adicet Bio (NASDAQ: ACET) — Perfil da empresa, notícias e dados financeiros
Adicet Bio is a biotechnology company focused on innovative cell therapies for cancer, leveraging gamma delta T cells in immuno-oncology.
Adicet Bio
Adicet Bio (NASDAQ:ACET) is a biotechnology company focused on the development and commercialization of cutting-edge cell therapies for cancer and other diseases. Trading exclusively on the NASDAQ with the symbol ACET, this firm is dedicated to innovating within the field of immuno-oncology, leveraging its expertise in gamma delta T cells to create novel treatments aimed at improving patient outcomes. Its projects include a diverse pipeline of proprietary allogeneic gamma delta T cell candidates designed to harness the innate and adaptive immune system. The objective of Adicet Bio is not only to advance its leading candidates through clinical trials but also to redefine the landscape of cell therapies, making significant strides in the fight against cancer.
Resumo
Operações
Produtos e/ou serviços de Adicet Bio
- Developing 'gamma delta T cell' therapies targeting hematologic and solid tumors, highlighting its innovative cancer treatment approach.
- Advancement of ADI-001, aiming for B-cell non-Hodgkin's lymphoma, showcasing targeted cell therapy capabilities.
- Exploration of ADI-002 for solid tumors, emphasizing the versatility in treating various cancer types.
- Research on 'off-the-shelf' allogeneic gamma delta T cell products, offering potential for scalable cancer treatment options.
- Investment in gamma delta T receptor platform technology, underpinning the company's innovative therapeutic development.
- Collaboration with leading pharmaceutical companies to enhance research and development efforts in cancer therapy.
equipe executiva do Adicet Bio
- Chen SchorCEO, President & Director
- Blake AftabSenior VP & Chief Scientific Officer
- Lloyd KlicksteinInterim Chief Medical Officer & Director
- Brian Nicholas HarveyChief Financial Officer
- Donald HealeyChief Technology Officer
- Amy LockeChief Human Resource Officer
Últimas notícias sobre a Adicet Bio
Histórico de dividendos
Dividendos por ação pagos pela Adicet Bio, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2018 | — | — | — | $0.0850 |
Principais indicadores financeiros
Resultados divulgados pela Adicet Bio, em USD.
- Cap. de mercado
- 35,7 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -10.5
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -122,1 mi | -116,8 mi | |
| 0 | -127,6 mi | -117,1 mi | |
| 0 | -152 mi | -142,7 mi | |
| 25 mi | -72,6 mi | -69,8 mi |